Drug Database
Back to search

Ireland· IE-PA-EU/1/04/285/1-20

Apidra 100 Units/ml Solution for injection

A insulins and analogues for injection, fast-acting product containing insulin glulisine, registered in Ireland by Aventis Pharma Deutschland GmbH. The same ATC class is registered in 2 of our 19 countries.

ATC A10AB

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedApidra 100 Units/ml Solution for inje…ATCA10ABREGISTER NO.IE-PA-EU/1/04/285/1-20PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insulin glulisineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin glulisine is registered in 2 of 19 countries.

Countries holding a registration under ATC A10AB (insulins and analogues for injection, fast-acting), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 1 of them publish a price we can compare per daily dose
Search insulin glulisine products by name

Insulin glulisine · ATC A10AB

2 / 19 countries

  • Finlandprice
  • Ireland
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Insulin glulisine
Manufacturer
Aventis Pharma Deutschland GmbH
Country
Ireland (IE)
ATC code
A10AB
ATC class
Insulins and analogues for injection, fast-acting
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/04/285/1-20

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Insulin glulisine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin glulisine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Apidra, Apidra Solostar
  • Liechtenstein · Apidra, Apidra Solostar
  • Norway · Apidra, Apidra Solostar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4fc847b5-1a2c-425d-b895-26e3d50ef51e
GET /v1/drugs/4fc847b5-1a2c-425d-b895-26e3d50ef51e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "routes": null,
  "source": "hpra",
  "atc_all": [
    "A10AB"
  ],
  "strength": null,
  "pa_number": "EU/1/04/285/1-20",
  "substances": [
    "Insulin glulisine"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "27/09/2004",
  "dispensing_status": "Product subject to prescription which may be renewed (B)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about insulin glulisine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console